Sort   by:  
 Page size 
UnknownEfficacy and safety of first-line osimertinib treatment and postprogression patterns of care in patients with epidermal growth factor receptor activating mutation-positive advanced non-small cell lung cancer (Reiwa study): study protocol of a multicentre, real-world observational study.
Not available
S-EPMC8728446 | biostudies-literature
UnknownClinical outcomes of patients with EGFR-mutated NSCLC developing interstitial lung disease during first-line osimertinib therapy: a sub-analysis of the Reiwa study.
Not available
S-EPMC11882494 | biostudies-literature
UnknownObservational study of the efficacy and safety of first-line osimertinib and later treatments for uncommon epidermal growth factor receptor-activating mutation-positive advanced non-small cell lung cancer.
Not available
S-EPMC11882500 | biostudies-literature
UnknownA phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations.
Not available
S-EPMC11420270 | biostudies-literature
UnknownCase report: Progressive pulmonary artery hypertension in a case of megalencephaly-capillary malformation syndrome.
Not available
S-EPMC10442816 | biostudies-literature
UnknownThe Whole Picture of First-Line Osimertinib for EGFR Mutation-Positive Advanced NSCLC: Real-World Efficacy, Safety, Progression Pattern, and Posttreatment Therapy (Reiwa Study).
Not available
S-EPMC11480219 | biostudies-literature
UnknownBevacizumab plus platinum-based chemotherapy in advanced non-squamous non-small-cell lung cancer: a randomized, open-label phase 2 study (CLEAR).
Not available
S-EPMC8350093 | biostudies-literature
UnknownPrognostic impact and gene expression analysis of peri-tumoral alveolar macrophage in resected lung adenocarcinoma.
Not available
S-EPMC10394127 | biostudies-literature
UnknownThe CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer.
Not available
S-EPMC8687755 | biostudies-literature
Sort   by:  
 Page size